Publications by authors named "Yusri Elsayed"

Claim this Profile
R
Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models.
Kodandaram Pillarisetti, Danlin Yang, Leopoldo Luistro, Jianhong Yao, Melissa Smith, Yusri A Elsayed

Blood· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias.
Min Chul Kwon, Jan Willem Thuring, Olivier Querolle, Xuedong Dai, Tinne Verhulst, Yusri Elsayed

Blood· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma.
Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, Raluca Verona, Diego Vieyra, Yusri Elsayed

Blood Adv· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, Arnob Banerjee, Tara Stephenson, Yusri Elsayed

Target Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, Arnob Banerjee, Tara Stephenson, Yusri Elsayed

Target Oncol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
Saad Z Usmani, Alfred L Garfall, Niels W C J van de Donk, Hareth Nahi, Jesus F San-Miguel, Yusri Elsayed

Lancet· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma.
Kodandaram Pillarisetti, Gordon Powers, Leopoldo Luistro, Alexander Babich, Eric Baldwin, Yusri Elsayed

Blood Adv· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma.
Kodandaram Pillarisetti, Suzanne Edavettal, Mark Mendonça, Yingzhe Li, Mark Tornetta, Yusri Elsayed

Blood· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia.
Priyanka Nair-Gupta, Michael Diem, Dara Reeves, Weirong Wang, Robert Schulingkamp, Yusri Elsayed

Blood Adv· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms.
William D Figg, Manish Monga, Donna Headlee, Avni Shah, Cindy H Chau, Yusri A Elsayed

Cancer Chemother Pharmacol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors.
Balaji Venugopal, Richard Baird, Rebecca S Kristeleit, Ruth Plummer, Richard Cowan, Yusri Elsayed

Clin Cancer Res· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer.
Kenneth J Pienta, Jean-Pascal Machiels, Dirk Schrijvers, Boris Alekseev, Mikhail Shkolnik, Yusri Elsayed

Invest New Drugs· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab.
Bertrand Coiffier, Weimin Li, Erin D Henitz, Jayaprakash D Karkera, Reyna Favis, Yusri A Elsayed

Clin Cancer Res· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial.
Pier Luigi Zinzani, Nuriet K Khuageva, Huaqing Wang, Bernardo Garicochea, Jan Walewski, Yusri A Elsayed

J Hematol Oncol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Bertrand Coiffier, Evgenii A Osmanov, Xiaonan Hong, Adriana Scheliga, Jiri Mayer, Yusri A Elsayed

Lancet Oncol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as end points of drug efficacy.
Sen H Zhuang, Liang Xiu, Yusri A Elsayed

Cancer J· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
George D Demetri, Sant P Chawla, Margaret von Mehren, Paul Ritch, Laurence H Baker, Yusri A Elsayed

J Clin Oncol· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study.
Donna E Reece, Vaishali Sanchorawala, Ute Hegenbart, Giampaolo Merlini, Giovanni Palladini, Yusri A Elsayed

Blood· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors.
Wells A Messersmith, Antonio Jimeno, David Ettinger, Dan Laheru, Julie Brahmer, Yusri Elsayed

Cancer Chemother Pharmacol· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.
Jean-Yves Blay, Margaret von Mehren, Brian L Samuels, Michael P Fanucchi, Isabelle Ray-Coquard, Yusri A Elsayed

Clin Cancer Res· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.
Carter Van Waes, Angela A Chang, Peter F Lebowitz, Colleen H Druzgal, Zhong Chen, Yusri A Elsayed

Int J Radiat Oncol Biol Phys· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.
Qin C Ryan, Donna Headlee, Milin Acharya, Alex Sparreboom, Jane B Trepel, Yusri Elsayed

J Clin Oncol· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Signal transduction--directed cancer treatments.
Edward A Sausville, Yusri Elsayed, Manish Monga, George Kim

Annu Rev Pharmacol Toxicol· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis